Throughout my career, I have heard dire warnings from my colleagues that technological advances would make the clinical practice of neuropsychology obsolete. As a graduate student in the 1970s, I can recall many neuropsychologists define the primary goal of assessment to identify the location of cortical lesions using neuropsychological testing. With the introduction of the CT scan, it was suddenly possible to view the soft tissue of the brain and provide a more precise localization of focal pathology, such as from strokes and tumors. One of my neuropsychology teachers at the time prophesized that neuroimaging would eliminate the need for neuropsychological assessments in the healthcare setting. Mark Twain's famous quip that "the reports of my death are greatly exaggerated" may equally apply to the rapid expansion of clinical neuropsychology services, despite the astounding technological advances in neuroimaging that have occurred since my days in graduate school.
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Today, many neuropsychologists view computerized testing as a threat to their clinical practice. The argument centers on the notion that physician referrals for neuropsychological assessments will be replaced by computerized neuropsychological examinations that provide meaningful clinical interpretations. All that a medical practice would require is the purchase of a computer/tablet and appropriate software. No doubt, in some settings, this concern is valid. However, in this opinion piece I argue that computerized testing has the capability of expanding clinical neuropsychological services to a broader range of patients in a wider range of clinical settings. This argument is based on the premise that an extraordinarily large number of patients who require neuropsychological services are simply not identified by current healthcare practices because, unlike blood pressure or weight, cognition is rarely measured during routine medical visits. With the growing interest in integrated care and shift to a population health-based reimbursement model in the US, there will be an increased need for valid, reliable cognitive screening measures that can be incorporated seamlessly into a standard medical visit with minimal disruption of service delivery flow or need for additional personnel.
My goals for this paper are to briefly outline our experiences with the development and implementation of neuropsychological screening assessments administered via an iPad. I will discuss how this project developed and provide two illustrative examples. Rather than being the death knell of neuropsychology, I argue that well-designed computerized cognitive measures that allow for screening of large numbers of patients will increase the demand for neuropsychological services and that neuropsychologists, due to our expertise in assessment, should be leading the development of computerized cognitive tests (I recognize that there are numerous computerized cognitive tests available and will not review this literature. My goal is to describe our experiences in integrating self-administered computerized testing into the clinical environment and provide some pragmatic recommendations.).
The development of these self-administered iPad assessment tools at the Cleveland Clinic has been ongoing for the past four years. The team (see list of names in the Acknowledgments section below) has consisted of clinical neuropsychologists, neurologists, biomedical engineers, computer scientists, and clinical and administrative support staff. Financial support for these efforts have come from pharmaceutical companies, private foundations, and philanthropy.
Multiple Sclerosis
We previously demonstrated the prevalence of cognitive dysfunction in MS to be in the 40-65% range [for a review, see Rao (1995) ]. Most importantly, despite a plethora of other symptoms (e.g., visual and motor disturbances, bowel and bladder problems), cognitive deficits have the greatest impact on activities of daily living (Rao et al., 1991) . Despite the frequency of cognitive dysfunction in MS and the availability of reliable and validated cognitive screening tests, cognitive testing is rarely, if ever, administered routinely in MS clinics. The majority of patients with MS who present for neuropsychological testing do so based on self-reported cognitive symptoms which are known to be weakly correlated with standard neuropsychological measures (Carone, Benedict, Munschauer, Fishman, & Weinstock-Guttman, 2005; O'Brien et al., 2007) . In addition, healthcare professionals, without the benefit of neuropsychological testing, are also inaccurate in detecting the often subtle cognitive deficits associated with MS (Romero, Shammi, & Feinstein, 2015) . Consequently, a large number of patients with cognitive deficits are not receiving neuropsychological services due to faulty screening procedures.
The Symbol Digit Modalities Test (SDMT) (Smith, 1982) , has been shown to be a reliable test that correlates well with other outcomes, such as employment (Benedict et al., 2017) , and has been used widely used internationally as a monitoring tool (Benedict et al., 2012) and in clinical trials (Benedict et al., 2017) . Because of its brief administration time (90 s) and sensitivity to MS-related cognitive disturbance, the SDMT is the most likely candidate test for screening cognitive disturbance in the MS clinic. Yet, in conversations with various directors of busy MS clinics, the SDMT is rarely administered due to personnel time associated with administration, scoring, conversion of raw scores using normative data, and entering results into the electronic medical record (EMR).
To address these concerns, we developed the Multiple Sclerosis Performance Test (MSPT) (Rudick et al., 2014) , a selfadministered computerized battery of cognitive, vision and motor tasks based on the iPad platform. The MSPT is currently integrated into our clinical environment. MS patients arrive for their clinical appointment 30 minutes prior to meeting their caregiver and take the MSPT without the need of a technician being present. Once the MSPT is completed, demographic and raw test data are immediately transferred to the cloud, scored, and converted to z-scores based on a normative database that automatically adjusts performance levels based on the patient's age, education, sex, race, and ethnicity. An electronic reporting form has been created such that adjusted scores are graphed for each test module and plotted with the current and previous test sessions to examine disease progression.
The cognitive measure from the MSPT is called the Processing Speed Test (PST), which closely resembles the SDMT. The PST has excellent retest reliability, demonstrates a strong correlation with the SDMT, was slightly more sensitive than SDMT in discriminating MS from healthy control groups, and correlated better with cerebral T2 lesion load than did the SDMT. Finally, PST performance was no different with or without a technician present in the testing environment, a key element in validating the self-administration approach (Rao et al., 2017) .
We introduced the MSPT to the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic in September of 2015. During the first full year, nearly 1,600 examinations were conducted in 1,300 unique patients as part of their routine clinical care. For 2017, we are projecting over 6,000 examinations in 4,500 unique patients. A network of at least 10 of the leading MS centers in the US will begin using the MSPT in 2017.
Most importantly, we have educated our caregiver professionals that a low score on the PST is not the end of the assessment of cognition in MS patients, but the beginning. Referrals for neuropsychological services have increased since the introduction of the PST into clinical practice. Furthermore, the referrals are more appropriate than those previously based on patient self-report or physician mental status assessment. Finally, we have begun to conduct research on the registry emanating from this clinic population. Most of our knowledge of cognitive dysfunction in MS emanates from patients who volunteer for research projects. The PST is administered to patients as part of their routine clinical care enabling us to collect data on a very large, consecutive series of patients with MS.
Alzheimer's Disease
Neuropathological changes associated with late onset Alzheimer's disease (LOAD) are thought to develop at least a decade prior to the diagnosis of Mild Cognitive Impairment (MCI) and LOAD (Jack et al., 2010; Morris et al., 1996; Price & Morris, 1999) . This period of time is referred to as the preclinical stage. Successful interventions designed to alter early neuropathological changes during the preclinical stage can increase the probability of delaying or preventing the onset of AD. To properly test the efficacy of interventions administered during the preclinical stage, it is critical to identify individuals at the highest risk for developing AD. Identification of valid assessment methods for identifying cognitively intact elders at greatest risk for AD is sorely needed. PET amyloid imaging and CSF biomarkers of amyloid and tau have evolved for detecting evidence of the AD pathophysiological processes in preclinical elders (Sperling et al., 2011) . The high costs of imaging and low rates of compliance with lumbar punctures (<50%) make wide scale screening for preclinical AD impractical for clinical trials designed to prevent or slow disease progression.
In contrast, longitudinal neuropsychological studies conducted a decade prior to dementia onset document a long period of gradual cognitive decline in episodic memory as well as non-memory domains during the preclinical stage. Importantly, the preclinical trajectory suggests not only a long-and slow-rate of presymptomatic change but also a period of acceleration of performance decrement that may begin several years before MCI onset (Howieson et al., 2008) .
Thus neuropsychological testing offers a low cost, rapid, and practical method for screening large numbers of healthy elders to identify persons who may be experiencing the preclinical stage of LOAD. The ideal clinical setting for screening atrisk elders is the primary care clinic. A lofty goal would be to assess cognition as often as blood pressure. However, directors of primary care clinics are even less disposed to allocate personnel resources to administering non-computerized neuropsychological tests than directors of specialty clinics.
To address this need, we developed the 16-minute Cleveland Clinic Computerized Cognitive Battery (C4B), which consists of three self-administered iPad-based measures of episodic learning and delayed recall, information processing speed (PST), and a measure of sequencing and switching executive functions. By the end of 2017, we will have completed normative and validation studies. In early 2018, we intend to integrate the C4B into Cleveland Clinic primary care clinics. Patients will take the C4B in the clinic waiting room with the iPad on their lap and test instructions presented via noise-canceling headphone sets. Testing is conducted prior to their visit so that the caregiver professional has access to both the raw and norm-corrected scores during the same clinic visit. Before launching this project in the primary care practices, we will develop a carepath to guide the clinical staff in the correct interpretation of the results and how to proceed with follow-up testing. Thus, such a battery should increase the number of referrals to dementia clinics that rely heavily on comprehensive neuropsychological services.
Importantly, low cost, self-administered cognitive screening conducted in the primary care clinic could be the first step for identifying persons in the preclinical stage of LOAD, where presumably drug intervention is likely to have the greatest impact. Persons who are flagged using a cognitive battery would then undergo testing for AD biomarkers (PET, CSF, MRI) and, if positive for LOAD, would then undergo disease-modifying drug treatment as they become available in the coming years.
Conclusions
I have used two examples where integrating self-administered computerized cognitive screening tests into large volume clinical practice can improve healthcare with little cost to the healthcare system. Importantly, these measures are integrated instantaneously into the EMR in a meaningful way allowing for immediate and useful feedback to the entire clinical team. This approach embodies the philosophy of integrated care. Our experience with MS patients also demonstrates that such an approach will only expand neuropsychology referrals, since many more patients will be identified with cognitive disorders than is currently the case. The current interest in integrated care as well as growing emphasis on population health provide unique opportunities for neuropsychologists to take the lead in developing reliable and valid computerized screening tests that can be easily integrated into busy specialty and primary care clinics to benefit our patients and the profession. If we don't take advantage of this opportunity, others will.
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